The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not
classically “druggable,” including loss-of-function mutations in tumor suppressor genes …

Synthetic lethality has long been proposed as an approach for targeting genetic defects in
tumours. Despite a decade of screening efforts, relatively few robust synthetic lethal targets …

CRISPR-Cas9 is a Nobel Prize-winning robust gene-editing tool developed in the last
decade. This technique enables a stable genetic engineering method with high precision on …

CRISPR/Cas9-based tools have rapidly developed in recent years. These include CRISPR-
based gene activation (CRISPRa) or inhibition (CRISPRi), for which there are libraries …

Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology
never advance to receive US Food and Drug Administration approval. While lack of efficacy …

Unraveling the mechanism of action and molecular target of small molecules remains a
major challenge in drug discovery. While many cancer drugs target genetic vulnerabilities …

Two genes are synthetic lethal if mutations in both genes result in impaired cell viability,
while mutation of either gene does not affect the cell survival. The potential usage of …

Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …

In the past decade, the development of a genome-editing technology mediated by CRISPR
has made genetic engineering easier than ever, both in vitro and in vivo. CRISPR systems …